About Us | Contact

Jonathan Hill Burdette Investigator

Neuroradiology North Carolina Baptist Hospital NPI1528043940
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$97,253.15
from 31 payments in the last 6 years

Total Cash or Cash Equivalent

$97,253.15
from 31 payments in the last 6 years

Total In-kind Items & Services

$0.00
from 0 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
12/07/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $87.50 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848609813
02/04/2021 Research Cash or cash equivalent $300.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION
Clinical Trials Gov ID NCT04280081
Payment Record ID 819444487
04/20/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $2000.00 Details
Payment from Celgene Corporation
Payment Record ID 783683557
11/06/2020 Research Cash or cash equivalent $600.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION
Clinical Trials Gov ID NCT04280081
Payment Record ID 728721645
03/18/2020 Research Cash or cash equivalent $175.00 Details
Payment from Eli Lilly and Company
Paymment Research Study LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Payment Record ID 728721223
11/30/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $5160.00 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 682107657
12/11/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $350.00 Details
Payment from PFIZER INC.
Payment Record ID 673841807
07/01/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $1225.00 Details
Payment from PFIZER INC.
Payment Record ID 673841805
07/11/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $875.00 Details
Payment from PFIZER INC.
Payment Record ID 673841803
08/19/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $350.00 Details
Payment from PFIZER INC.
Payment Record ID 673841801
10/09/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $350.00 Details
Payment from PFIZER INC.
Payment Record ID 673841799
11/20/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $350.00 Details
Payment from PFIZER INC.
Payment Record ID 673841665
09/03/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $350.00 Details
Payment from PFIZER INC.
Payment Record ID 673841663
05/22/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $1207.50 Details
Payment from PFIZER INC.
Payment Record ID 672591989
02/14/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $584.50 Details
Payment from PFIZER INC.
Payment Record ID 672591811
03/13/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $612.50 Details
Payment from PFIZER INC.
Payment Record ID 672591807
04/04/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $525.00 Details
Payment from PFIZER INC.
Payment Record ID 672591803
02/01/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $1662.50 Details
Payment from PFIZER INC.
Payment Record ID 672591797
07/03/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $7350.00 Details
Payment from PFIZER INC.
Payment Record ID 610385953
09/10/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $1225.00 Details
Payment from PFIZER INC.
Payment Record ID 610385949
02/07/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $4200.00 Details
Payment from PFIZER INC.
Payment Record ID 610385431
10/18/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $1365.00 Details
Payment from PFIZER INC.
Payment Record ID 610385425
09/04/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $1662.50 Details
Payment from PFIZER INC.
Payment Record ID 610384927
11/21/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $6387.50 Details
Payment from PFIZER INC.
Payment Record ID 506142869
07/27/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $10265.50 Details
Payment from PFIZER INC.
Payment Record ID 506142865
04/12/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $14350.00 Details
Payment from PFIZER INC.
Payment Record ID 506142861
12/07/2017 Research Cash or cash equivalent $12250.00 Details
Payment from GUERBET LLC
Paymment Research Study Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Clinical Trials Gov ID NCT02633501
Payment Record ID 495464755
03/23/2017 Research Cash or cash equivalent $4210.15 Details
Payment from GUERBET LLC
Paymment Research Study Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Clinical Trials Gov ID NCT02633501
Payment Record ID 495464747
09/14/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $8253.00 Details
Payment from Pfizer Inc.
Payment Record ID 404846358
04/21/2016 Research Cash or cash equivalent Drug $5995.00 Details
Payment from GE HEALTHCARE
Paymment Research Study 114-2015-GES-0056
Payment Record ID 384385320
08/04/2016 Research Cash or cash equivalent $2975.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 2 STUDY OF LY2157299 MONOHYDRATE MONOTHERAPY OR LY2157299 MONOHYDRATE PLUS LOMUSTINE THERAPY COMPARED TO LOMUSTINE MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Clinical Trials Gov ID NCT01582269
Payment Record ID 372520876
;